 |
 |
| Home |
| Clinical Trial Search |
| Mailing List |
| Clinical Trial FAQs |
| Participation FAQs |
| Clinical Trials Glossary |
| About Informed Consent |
| Medical Research Areas |
| Clinical Trial Links |
| How to use this System |
|
This site is intended for U.S. residents only. For Novartis Worldwide, Click here |
|
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
|
|
|
|
|||
Clinical Trial Search
Kidney Transplantation
A kidney transplant is an operation that places a healthy kidney in the body. The transplanted kidney takes over the work of the two kidneys that failed, and dialysis is no longer needed. [Source: www.nlm.nih.gov/medlineplus]
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Study Assessing Gastrointestinal Symptoms Post Kidney Transplant Surgery CERL080AUS67
The purpose of this clinical research study is to determine if the FDA-approved study drug Myfortic® can replace CellCept® and be safely increased in dose, in people who have had a kidney transplant and who have had their CellCept® dose reduced due to gastrointestinal side effects. Participants must be at least 18 years and will be asked to visit the study center 4 times over a 6 week period. CellCept® and myfortic® have been approved by the U.S. Food and Drug Administration (FDA) for post kidney transplant treatment.
Trial phase: Phase 4 Participation Duration: Participants will be required to visit the study center 4 times over a 6 week period. Protocol Number: CERL080AUS67 |
